Compare Autozone Inc (AZO) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Autozone Inc vs TG Therapeutics Inc — how do they compare? Autozone Inc trades at $3,042 (market cap $49.67B), while TG Therapeutics Inc trades at $49.44 (market cap $7.64B). The key difference: Autozone Inc is far larger — about 6.5× TG Therapeutics Inc's market cap, and TG Therapeutics Inc is trading nearer its 52-week high, Autozone Inc nearer its low. Which is the better fit depends on your goals.
| AZO | TGTX | |
|---|---|---|
Market Cap | $49.67B | $7.64B |
Sector | Consumer Cyclical | Health |
52-Week High | $4.35K | $59.06 |
52-Week Low | $2.92K | $26.94 |
Enterprise Value | $62.05B | $7.84B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AutoZone (AZO) trades at $3,045.87, down 0.72% with bearish technical signals despite strong analyst support. The company maintains solid fundamentals with $18.94B revenue and 12.4% net margin, though recent Q3 2025 EPS missed expectations while Q4 2025 and Q1 2026 beat. Operating cash flow remains robust at $3.12B, supporting ongoing expansion initiatives. Recent organizational changes and international growth strategies highlight management's focus on long-term value creation.
AZO presents a compelling value opportunity with 72.7% analyst buy ratings and $3,730 consensus price target representing 22% upside. Key risks include margin compression trends and competitive pressures in auto parts retail. The stock's current technical weakness contrasts with strong institutional conviction, creating potential for recovery if earnings momentum improves.
TG Therapeutics (TGTX) trades at $49.50, up 0.69% today, with a bearish technical signal from moving averages despite neutral oscillators. The company reported strong revenue growth, with Q2 2026 sales reaching $240 million and raised full-year guidance to $950 million, though it missed earnings estimates for three consecutive quarters. Profitability metrics remain robust with a net income margin of 55.22% and ROE exceeding 100%, but valuation ratios like EV/EBITDA at 56.26 suggest premium pricing.
The outlook is mixed: bullish analyst sentiment with an 84.6% buy rating and a $63.75 price target offers upside potential, driven by Briumvi's commercial success and expansion into schizophrenia trials. However, risks include earnings misses, a shareholder investigation into fiduciary duties, and high cash burn in 2025. Investors should weigh strong revenue momentum against execution risks and elevated valuations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Autozone Inc
AutoZone is the premier seller of aftermarket automotive parts, tools, and accessories to do-it-yourself customers in the United States. The company derives an increasing proportion of its sales from domestic commercial customers, although its presence in its home market is still dominated by its do-it-yourself operation, which accounts for nearly 75% of sales in country. AutoZone also has a growing presence in Mexico and Brazil. AutoZone had 6,767 stores in the U.S. (6,051), Mexico (664), and Brazil (52) as of the end of fiscal 2021.
Read more on AZO →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
